Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TORONTO, Sept. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Senior Director, Investor Relations. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . - Q3 2022 Consolidated. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Theratechnologies Inc. Stockhouse. It's a different kind of fat that may require a different type of treatment. Stockhouse. Who is Theratechnologies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Stockhouse. P. 5000 0. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. By continuing to use our service, you agree to our use of cookies. T. -4. - On track to meet FY2022. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. See a list of the most recent Stock Forum posts on Stockhouse. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. stock price gained 6. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Jan. . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Find the latest Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies Inc. com. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 68 to a day high of $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. We also use them to share usage. 54% and a negative trailing twelve-month return on equity of. Theratechnologies to Announce Financial Results for Its First Quarter 2022. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Cash, bonds and money market funds of US$22. com. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. com uses cookies on this site. 617-356-1009. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. Theratechnologies layoffs. ET. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. However, it did not meet the equivalence limits of 0. com uses cookies on this site. MONTREAL, Sept. About Theratechnologies. Stockhouse. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gary Littlejohn. Investor inquiries: Elif McDonald. Cookies are used to offer you a better browsing. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. MONTREAL, Oct. 74M. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. 03) EPS for the quarter, beating the consensus estimate of ($0. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. home message. TH | September 26, 2023. Further. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 81 million for the quarter. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. Theratechnologies had a negative net margin of 36. S. View Company Info for Free. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Shares of Theratechnologies are up 4. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Biopharmaceutical company Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. For investor inquiries: Leah Gibson. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. By continuing to use our service, you agree to our use of cookies. 9 million and US. 00, suggesting a possible upside of. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. GUD | Complete Knight Therapeutics Inc. GUD | Complete Knight Therapeutics Inc. TH 48% v4,15M c1. We also use them to share. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. Stockhouse. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. 4%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. S. By continuing to use our service, you agree to our use of cookies. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. - Q3 2022 Consolidated Revenue Growth of 17% to $20. Theratechnologies inc. 00. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. TH | February 28, 2023. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 9% more than in 2021. T. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. MONTREAL, Oct. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. Pour les émetteurs. 8 million. Share your ideas and get valuable. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. This news release constitutes a “designated news release” for the purposes of the Company’s. Market Cap. Q3 2023 consolidated revenue of $20. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. 9 million as at August 31, 2023. T. stock news by MarketWatch. We also use them to share usage information with our partners. Agreement in principle on key amendments to loan. TORONTO, May 19, 2023. 33. By continuing to use our service, you agree to our use of cookies. Image source: The Motley Fool. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. : Renegotiated Lease to Generate Substantial Annual Savings. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. By continuing to use our service, you agree to our use of cookies. 5% workforce reduction. 63. Register for your free account today at data. 1-438. : 001-35203 Mr. Stockhouse. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, Aug. By continuing to use our service, you agree to our use of cookies. 72%. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. Cookies are used to offer you a better browsing experience and to. 4%. Unveiling Silvercorp's golden potential at the Ying Mining District. 5000 +0. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Cookies are used to offer you a better browsing experience and to analyze our traffic. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. US Headquarters. THTX earnings call for the period ending February 29, 2020. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Focused on small-cap companies and sectors. We currently market prescription products for people with HIV in the United States. FDA for its IV push form of administration of Trogarzo. Montréal, Québec, Canada . 25. com uses cookies on this site. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. During the last trading day the stock fluctuated 12. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. By continuing to use our service, you agree to our use of cookies. Stockhouse. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Trogarzo® and. The company reported ($0. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. By continuing to use our service, you agree to our use of cookies. Free cash flow. (Image via Theralase Technologies Inc. TH | July 20, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. MONTREAL, Sept. The webinar will also address system-level barriers and present real-world. 67, which is an increase of 1,144. Theratechnologies Inc. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. 2% to $21. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Find the latest Theratechnologies Inc. Stockhouse. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Cookies are used to offer you a better browsing experience and to analyze our traffic. 40%. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. Senior Director, Investor Relations. 16%. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Betteryear2. THTX | Complete Theratechnologies Inc. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. MONTREAL, Oct. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. By Nick Paul Taylor Jul 12, 2023 8:57am. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. This news release constitutes a “designated news release” for the purposes of the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Phone Number (514) 336-7800. 1-514-336-7800. We also use them to share usage. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. US Headquarters. By continuing to use our service, you agree to our use of cookies. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Browse posts by Sector and Subsector. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". Further. com uses cookies on this site. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | Complete Theratechnologies Inc. FY2022 revenue. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company develops treatments for lipodystrophy . lgibson. stock news by MarketWatch. Stockhouse. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. com uses cookies on this site. 81 million for the quarter. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . Further. Further. Stockhouse. Theratechnologies Stock Price, News and Company Updates. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Forecast to breakeven in 2024 Jul 15. 2% per year. MONTREAL, Oct. When this page refreshes you will be logged in with the new address. Stockhouse. . MONTREAL, Sept. However, only about 4% of the stocks on the OTC market fall into this category. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. 06 million, an increase of 14. com uses cookies on this site. com. . Stockhouse. About SORT1+ Technology™ and TH1902. MONTREAL, Aug. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Cookies are used to offer you a better browsing experience and to analyze our traffic. Statut du système de négociation. We also use them to share usage. com uses cookies on this site. Contact Email communications@theratech. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. Investor Relations. Watch list NEW Set a price target alert After Hours Last. com uses cookies on this site. Real-time discussion about Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Learn why it. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Stockhouse. WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. In the United States, Trogarzo ® (ibalizumab. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. com uses cookies on this site. Stockhouse. Visit the TSX ETF Investor Centre to access our screener and comparison tool. The abstracts are now available at aacr. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. OTCQX – this is the premium tier of OTC stocks. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Phone Number 15143319691. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. VANCOUVER, British Columbia, Nov. 8. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage information with our partners. R. Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. . MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies.